Co-Diagnostics
CODX
69 hedge funds and large institutions have $40.6M invested in Co-Diagnostics in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 20 closing their positions.
80% more call options, than puts
Call options by funds: $4.53M | Put options by funds: $2.52M
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
0.03% more ownership
Funds ownership: 0.68% → 0.71% (+0.03%)
5% less capital invested
Capital invested by funds: $42.7M → $40.6M (-$2.14M)
16% less funds holding
Funds holding: 82 → 69 (-13)
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.44M |
| 2 |
GC
Globeflex Capital
San Diego,
California
|
+$1.12M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$811K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$767K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$558K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.06M |
| 2 |
ARC
Advisor Resource Council
Dallas,
Texas
|
-$1.02M |
| 3 |
EGM
Engineers Gate Manager
New York
|
-$754K |
| 4 |
Jane Street
New York
|
-$480K |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$307K |
CODX Hedge Fund Activity: Q2 2022 in Review
69 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q2 2022, worth a combined $40.6M — down 5% from $42.7M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CODX and 9 opened new positions — a net loss of 11 holders — while 17 trimmed existing stakes and 26 added.
The largest buyer was Morgan Stanley, adding an estimated $2.44M. The largest seller was Millennium Management, cutting an estimated $1.06M.
- 69 institutional investors held Co-Diagnostics (CODX) as of Q2 2022, down from 82 in Q1 2022.
- Funds reported $40.6M of Co-Diagnostics stock for Q2 2022, down 5% quarter-over-quarter.
- 9 funds opened new Co-Diagnostics positions in Q2 2022 and 20 closed out, a net change of -11 holders.
- The largest Co-Diagnostics buyer in Q2 2022 was Morgan Stanley, an estimated $2.44M added.
- The largest Co-Diagnostics seller in Q2 2022 was Millennium Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q2 2022.